CN111201030B - 通过阻断tim-3和其配体的相互作用治疗癌症 - Google Patents

通过阻断tim-3和其配体的相互作用治疗癌症 Download PDF

Info

Publication number
CN111201030B
CN111201030B CN201880061694.6A CN201880061694A CN111201030B CN 111201030 B CN111201030 B CN 111201030B CN 201880061694 A CN201880061694 A CN 201880061694A CN 111201030 B CN111201030 B CN 111201030B
Authority
CN
China
Prior art keywords
cdr
antibody
gal3
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880061694.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111201030A (zh
Inventor
D·孙
Y·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Co ltd
Zhenhe Pharmaceutical Co ltd
Original Assignee
Immunity Co ltd
Zhenhe Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Co ltd, Zhenhe Pharmaceutical Co ltd filed Critical Immunity Co ltd
Publication of CN111201030A publication Critical patent/CN111201030A/zh
Application granted granted Critical
Publication of CN111201030B publication Critical patent/CN111201030B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880061694.6A 2017-07-25 2018-07-24 通过阻断tim-3和其配体的相互作用治疗癌症 Active CN111201030B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762536886P 2017-07-25 2017-07-25
US62/536,886 2017-07-25
PCT/US2018/043513 WO2019023247A1 (en) 2017-07-25 2018-07-24 TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND

Publications (2)

Publication Number Publication Date
CN111201030A CN111201030A (zh) 2020-05-26
CN111201030B true CN111201030B (zh) 2024-11-01

Family

ID=65040896

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880061694.6A Active CN111201030B (zh) 2017-07-25 2018-07-24 通过阻断tim-3和其配体的相互作用治疗癌症

Country Status (7)

Country Link
US (3) US12227567B2 (https=)
EP (1) EP3658172A4 (https=)
JP (2) JP7368856B2 (https=)
CN (1) CN111201030B (https=)
AU (1) AU2018308088B2 (https=)
CA (1) CA3070446A1 (https=)
WO (1) WO2019023247A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
JP7539834B2 (ja) * 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
AU2020214796A1 (en) * 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
EP4684799A2 (en) 2019-12-06 2026-01-28 TrueBinding, Inc. Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof
WO2021146218A1 (en) * 2020-01-13 2021-07-22 Truebinding, Inc. Anti-gal3 antibodies and methods of use
JP7421400B2 (ja) * 2020-03-30 2024-01-24 アークレイ株式会社 ヒトガレクチン－３の分析、検出、測定に関する抗体、方法及びキット
WO2021242776A2 (en) * 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
US20240026009A1 (en) * 2020-12-08 2024-01-25 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
CA3238590A1 (en) 2021-11-09 2023-05-19 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases

Family Cites Families (764)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE398176T1 (de) 1991-12-06 2008-07-15 Max Planck Gesellschaft Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
DE69429925T2 (de) 1993-10-20 2002-10-02 Duke University, Durham METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
WO1996006862A1 (en) 1994-08-26 1996-03-07 Human Genome Sciences, Inc. Gabaa receptor epsilon subunit
EP0791067B1 (en) 1994-10-28 2008-12-17 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Protein kinase npk-110
US6835555B1 (en) 1994-11-01 2004-12-28 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5650313A (en) 1995-06-05 1997-07-22 Human Genome Sciences, Inc. Ubiquitin conjugating enzymes 8 and 9
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP4073955B2 (ja) 1995-07-07 2008-04-09 ダーウィン モレキュラー コーポレイション アルツハイマー病に関連する第１染色体の遺伝子および遺伝子産物
US6156311A (en) 1995-07-27 2000-12-05 The American National Red Cross Modulators of expression and function of LRP in alzheimer's disease
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AUPN896596A0 (en) 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
EP0890105B1 (en) 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US5663059A (en) 1996-05-10 1997-09-02 Incyte Pharmaceuticals, Inc. Human phospholipase inhibitor
US6010878A (en) 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
JP4649602B2 (ja) 1997-02-07 2011-03-16 アメリカ合衆国 活性依存性向神経第▲ｉｉｉ▼因子（ａｄｎｆ▲ｉｉｉ▼）
US6087153A (en) 1997-07-24 2000-07-11 The Trustees Of Columbia University In The City Of New York Sel-10 and uses thereof
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7384910B2 (en) 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7189703B2 (en) 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
GB9816575D0 (en) 1998-07-31 1998-09-30 Zeneca Ltd Novel compounds
US20050032675A1 (en) 1998-08-06 2005-02-10 Teijin Limited Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
WO2000007624A2 (en) 1998-08-06 2000-02-17 Teijin Limited Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE69930328T2 (de) 1998-08-27 2006-12-14 Spirogen Ltd., Ryde Dimere Pyrrolobenzodiazepine
EP1114861B8 (en) 1998-09-17 2008-10-01 Otsuka Pharmaceutical Co., Ltd. Ly6h gene
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2002531815A (ja) 1998-12-02 2002-09-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア オキシダント・ストレス症候群および疾病における脂質の過酸化のレベルを決定する方法および組成物
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
DE19909357A1 (de) 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
DE19910108C2 (de) 1999-03-08 2001-02-22 Falk Fahrenholz Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie
AU4055000A (en) 1999-04-13 2000-11-14 Daniel K. Hsu Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001004299A1 (en) 1999-07-08 2001-01-18 Helix Research Institute AMYLOID β PROTEIN AGGLUTINATION CONTROLLING FACTOR
DE69903278D1 (de) 1999-07-09 2002-11-07 Inst Pasteur De Lille Lille Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
AU783964B2 (en) 1999-08-06 2006-01-05 S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US6255054B1 (en) 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
US7410757B1 (en) 1999-09-17 2008-08-12 Keio University Method of screening disease depressant gene
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU2001232275A1 (en) 2000-02-14 2001-08-20 Bf Research Institute, Inc. Novel collagen-like protein clac, precursor thereof and genes encoding the same
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
US20060148712A1 (en) 2000-03-13 2006-07-06 Fu-Tong Liu Monocyte chemoattractant activity of galectin-3
WO2001068123A2 (en) 2000-03-13 2001-09-20 La Jolla Institute For Allergy And Immunology Monocyte chemoattractant activity of galectin-3
ES2389811T3 (es) 2000-06-28 2012-10-31 Prana Biotechnology Limited Oligómeros de amiloide beta para uso en el tratamiento, el alivio o la prevención de la enfermedad de Alzheimer
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CN1187596C (zh) 2000-09-21 2005-02-02 松下电器产业株式会社 扫描探针显微镜,及其探针和制造方法,及使用其的分子加工法
US7471798B2 (en) * 2000-09-29 2008-12-30 Knowles Electronics, Llc Microphone array having a second order directional pattern
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
CN1549721B (zh) 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
DE60227650D1 (de) 2001-04-14 2008-08-28 Evotec Neurosciences Gmbh Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer-krankheit und relatierte neurodegeneratiefe störungen
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE10130247A1 (de) 2001-06-22 2003-01-16 Elegene Ag I Ins Identifizierung von ses-3 sowie dessen Verwendungen
DE10130166A1 (de) 2001-06-22 2003-01-16 Elegene Ag I Ins Identifizierung von ses-1 sowie dessen Verwendungen
US6831699B2 (en) 2001-07-11 2004-12-14 Chang Industry, Inc. Deployable monitoring device having self-righting housing and associated method
DE60226036T9 (de) 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
EP1423704B1 (en) 2001-09-07 2010-04-14 Takeda Pharmaceutical Company Limited Diagnostic and therapeutic use of f-box proteins for alzheimer's disease and related neurodegenerative disorders
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
AU2003208857A1 (en) 2002-02-14 2003-09-04 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of caps
CA2478636A1 (en) 2002-03-04 2003-09-12 Nymox Corporation Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
CA2477675C (en) 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE365175T1 (de) 2002-03-21 2007-07-15 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
JP4662719B2 (ja) 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
AU2003224120A1 (en) 2002-04-24 2003-11-10 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
US20050032673A1 (en) 2002-06-10 2005-02-10 John Constance M. Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
US7409040B2 (en) 2002-06-21 2008-08-05 Reuven Avrohom Cyrulnik System and method for noninvasive diagnostic imaging, detection, and identification of substances by microwave/RF modulation of x-rays and applications in treatment of diseases characterized by the presence of pathological macromolecules or by the need for regeneration of normal tissue
AU2003260301A1 (en) 2002-06-27 2004-01-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
US7141137B2 (en) 2002-07-10 2006-11-28 University Of Maine System Board Of Trustees Method of making laminated wood beams with varying lamination thickness throughout the thickness of the beam
CN100572392C (zh) 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
MXPA05008156A (es) 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
EP1590673B1 (en) 2003-02-04 2009-04-15 EVOTEC Neurosciences GmbH Diagnostic use of scn2b for alzheimer's disease
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2004091634A1 (en) 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246105B1 (es) 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20060257946A1 (en) 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
US7384523B2 (en) 2003-07-10 2008-06-10 Radiometer Medical Aps Chloride ion selective membrane and sensor
CA2534249C (en) 2003-07-28 2010-05-11 Sig Technology Ltd. Pouring out closure with piercing edge arrangement for combipacks or containers sealed with foil material
MXPA06001558A (es) 2003-08-08 2006-05-15 Schering Corp Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico.
ES2323068T3 (es) 2003-08-08 2009-07-06 Schering Corporation Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida.
JPWO2005023286A1 (ja) 2003-09-05 2007-11-01 久光製薬株式会社 アルツハイマー病の予防及び／又は治療のための薬剤
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20060223065A1 (en) 2003-09-30 2006-10-05 Evotec Neuroscience Gmbh Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
US7700823B2 (en) 2003-10-02 2010-04-20 Aventis Pharma S.A. Transgenic animals exhibiting major disorders related to Alzheimer's disease
MXPA06003686A (es) * 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
GB0416511D0 (en) 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
US20070271619A1 (en) 2003-10-29 2007-11-22 Heinz Von Der Kammer Diagnostic and Therapeutic Use of the Human Dax-1 Gene and Protein for Neurodegenerative Diseases
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005058352A2 (en) 2003-12-17 2005-06-30 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
RU2006126122A (ru) 2003-12-19 2008-01-27 Бристол-Маерс Сквибб Компани (Us) Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
WO2005080435A1 (ja) 2004-02-20 2005-09-01 Immuno-Biological Laboratories Co., Ltd. モノクローナル抗体およびその利用
US8060179B1 (en) 2006-11-16 2011-11-15 Scientific Nanomedicine, Inc. Biomagnetic detection and treatment of Alzheimer's Disease
EP1721008B1 (en) 2004-03-03 2010-02-24 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005105998A1 (ja) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
US7629443B2 (en) 2004-06-02 2009-12-08 New York Blood Center, Inc. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
DK1794313T3 (da) 2004-06-21 2013-07-22 Proteome Sciences Plc Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein
CN1969277A (zh) 2004-07-07 2007-05-23 三菱电机株式会社 电力计算装置、电力计算方法、抗侵害性评价装置和抗侵害性评价方法
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
WO2006014638A2 (en) 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
DE602005007245D1 (https=) 2004-07-28 2008-07-10 Schering Corp
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
WO2006016644A1 (ja) 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation 抗体及びその利用
WO2006015976A1 (en) 2004-08-11 2006-02-16 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of a plasma membrane atpase
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
US20080193947A1 (en) 2004-10-08 2008-08-14 Ernst Heinen Complementary Peptides For Beta-Amyloid 29-42 Peptide
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
AU2006237903A1 (en) 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
PL1879901T3 (pl) 2005-04-21 2010-06-30 Medimmune Ltd Pirolobenzodiazepiny
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
NZ562434A (en) 2005-05-05 2010-04-30 Merck & Co Inc Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US8114620B2 (en) 2005-05-30 2012-02-14 Takeda Pharmaceutical Company Limited Diagnostic and therapeutic target PRKX proteins for neurodegenerative diseases
US20090133135A1 (en) 2005-06-01 2009-05-21 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases
CN101198597B (zh) 2005-06-14 2011-11-16 先灵公司 作为天冬氨酰基蛋白酶抑制剂的化合物的制备和用途
RU2008100164A (ru) 2005-06-14 2009-07-20 Шеринг Корпорейшн (US) Получение и применение соединений в качестве ингибиторов протеаз
US20100008921A1 (en) 2005-06-16 2010-01-14 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Target Adarb2 Proteins for Neurodegenerative Diseases
DE602006008460D1 (de) 2005-06-17 2009-09-24 Ca Nat Research Council NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
DE102005029729A1 (de) 2005-06-24 2006-12-28 Röchling Automotive AG & Co. KG Verkleidungs- oder Gehäuseteil eines Fahrzeugs und Verfahren zu seiner Herstellung
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
US20070021282A1 (en) 2005-07-19 2007-01-25 Karp Shaun A Abdominal exercising and strength testing systems
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
CA2630964A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US8263558B2 (en) 2005-11-30 2012-09-11 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP1992639A4 (en) 2006-02-22 2009-08-26 Hayashibara Biochem Lab PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF AN ANTIAMYLOID PEPTIDANT BODY
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
JP2009531332A (ja) 2006-03-23 2009-09-03 ライフ テクノロジーズ コーポレーション 癌細胞株のインビボイメージングのための方法及び試薬
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2007129457A1 (ja) 2006-04-25 2007-11-15 The University Of Tokyo アルツハイマー病および癌の治療薬
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
WO2008004346A1 (fr) 2006-07-06 2008-01-10 Nec Corporation Procédé et dispositif de conception d'une hiérarchie de circuit intégré semi-conducteur
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8105839B2 (en) 2006-09-06 2012-01-31 National University Corporation Tottori University Diagnostic kit for Alzheimer's disease, diagnostic marker, and detection method for indicator of pathological state thereof
WO2008036717A2 (en) * 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
WO2008085564A2 (en) 2006-09-20 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and methods involving truncated recombinant seven g-protein coupled receptors
US8420613B2 (en) 2006-11-15 2013-04-16 The J. David Gladstone Institutes Methods and compositions for reducing amyloid beta levels
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8420591B2 (en) 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
EP3225251B1 (en) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
JP2010515717A (ja) 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
PT2121754E (pt) 2007-01-18 2015-05-11 Lilly Co Eli Fab de beta-amilóide peguilado
WO2008112559A1 (en) 2007-03-09 2008-09-18 Regents Of The University Of California Suppression of galectin-3 for treating an inflammatory condition
EP2149584B1 (en) 2007-04-20 2017-12-13 The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
EP2140247B1 (en) 2007-04-26 2012-06-27 The Ludwig Institute for Cancer Research Method for modulating activity of t lymphocytes
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS
EP2152309B1 (en) 2007-05-14 2013-07-10 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
WO2009008980A2 (en) 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
US8618123B2 (en) 2007-07-17 2013-12-31 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
US8993833B2 (en) 2007-08-14 2015-03-31 Duke University Model of Alzheimer's Disease
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
WO2009033743A1 (en) 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8343493B2 (en) 2007-10-29 2013-01-01 Innogenetics N.V. Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs
US8445649B2 (en) 2007-10-29 2013-05-21 Tao Health Life Pharma Co., Ltd. Antibody and use thereof
CN101918564A (zh) 2007-11-01 2010-12-15 弗·哈夫曼-拉罗切有限公司 非人类四元转基因动物
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
KR101397554B1 (ko) 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
DK2207568T3 (en) 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
US8349579B2 (en) 2007-12-13 2013-01-08 Wayne State University Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer
JP5738599B2 (ja) 2008-01-07 2015-06-24 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 星状細胞腫の同定と分級を行う方法、星状細胞腫の同定と分級を行う際に使用するキット
ITNA20080006A1 (it) 2008-01-28 2009-07-29 Consiglio Nazionale Ricerche Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp
HUE031944T2 (en) 2008-02-08 2017-08-28 Immunas Pharma Inc Antibodies capable of specific binding of amyloid β-oligomers and their use
AU2009222199A1 (en) 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid beta activity of intravenous immunoglobulin (IVIG) in vitro
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
US9688734B2 (en) 2008-04-14 2017-06-27 Alzinova Ab Stable amyloid beta monomers and oligomers
MX2010012142A (es) 2008-05-09 2011-04-05 Abbott Gmbh & Co Kg Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
WO2009146301A1 (en) 2008-05-27 2009-12-03 Yale University TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
WO2009151618A2 (en) 2008-06-10 2009-12-17 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Methods and compositions for treating alzheimer's disease
WO2009155609A1 (en) 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
EP2303001A4 (en) 2008-06-20 2016-07-13 Janssen Biotech Inc METHOD FOR VERIFYING THE EFFECTIVENESS OF TREATMENT OF NEUROLOGICAL ILLNESSES
MX345039B (es) 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
US9045555B2 (en) 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
AU2009268808A1 (en) 2008-07-08 2010-01-14 Merck Sharp & Dohme Corp. Vaccine for the treatment of Alzheimer's disease
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
ME01898B (me) 2008-08-12 2014-12-20 Zinfandel Pharmaceuticals Inc Metoda za identifikaciju faktora rizika od alchajmerove bolesti
US8283322B2 (en) 2008-08-15 2012-10-09 Orthopeutics, Lp Formulations for nonsurgical exogenous crosslink therapy
WO2010040029A1 (en) 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
CN104198712A (zh) 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
EP2358912B1 (en) 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Methods for assessing rna patterns
AU2009314205A1 (en) 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Gamma secretase modulators
RU2011123862A (ru) 2008-11-13 2012-12-20 Шеринг Корпорейшн Модуляторы гамма-секретазы
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
US8912145B2 (en) 2008-11-28 2014-12-16 Hokko Chemical Industry Co., Ltd. Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease
EP3115063A3 (en) * 2008-12-03 2017-04-19 The John Hopkins University Galectin-3 and annexin-a2 as immunological target
US20120046181A1 (en) 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
US8759337B2 (en) 2008-12-22 2014-06-24 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20100196882A1 (en) * 2009-02-04 2010-08-05 Avraham Raz GALECTIN-3 nsSNP MARKER FOR CANCER
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
FR2942476B1 (fr) 2009-02-20 2013-03-15 Commissariat Energie Atomique Composes de type pyridocarbazole et leurs applications
SI2408807T1 (sl) 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
JP2010268789A (ja) 2009-04-24 2010-12-02 Kumamoto Univ 細胞医薬の製造方法
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
EP2273273A1 (en) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
WO2011007560A1 (en) 2009-07-15 2011-01-20 Fuji Electric Systems Co., Ltd. Super-junction semiconductor device
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
PL2463368T3 (pl) 2009-08-07 2018-07-31 Kyowa Hakko Kirin Co., Ltd. Humanizowane przeciwciało anty-oligomer amyloidu B
BR112012008063A2 (pt) 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
US8617549B2 (en) 2009-09-11 2013-12-31 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
DE102009043750A1 (de) 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
JPWO2011045945A1 (ja) 2009-10-16 2013-03-04 国立大学法人京都大学 アミロイドβのターン構造を認識する抗体
WO2011102901A1 (en) 2010-02-20 2011-08-25 Ebiotec (Euroespes Biotechnology) Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
EP2550361B1 (en) 2010-03-25 2017-02-08 The J. David Gladstone Institutes Compositions and methods for treating neurological disorders
TW201138807A (en) 2010-04-13 2011-11-16 Baxter Int Use of ventricular enlargement rate in intravenous immunoglobulin treatment of Alzheimer's disease
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
US20130065258A1 (en) 2010-05-25 2013-03-14 Makoto Watanabe Colorectal cancer marker galectin, method for analyzing galectin concentration in blood sample, and kit for detecting colorectal cancer marker galectin
EP2580326A1 (en) 2010-06-11 2013-04-17 Antisense Pharma GmbH Method for selective oligonucleotide modification
CA2805414C (en) 2010-07-14 2020-07-07 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US10420923B1 (en) 2010-08-10 2019-09-24 Amiram Katz Method and device for intrathecal administering of immunoglobulin
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
WO2012036786A1 (en) 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
EP2640404B1 (en) 2010-11-17 2017-02-22 Ben Gurion University of The Negev Research and Development Authority T-cell therapy to neurodegenerative diseases
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
EP2660600B1 (en) 2010-12-28 2018-08-08 Sumitomo Dainippon Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
EP2508212A1 (en) 2011-04-05 2012-10-10 Universitätsklinikum Freiburg Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
KR101589135B1 (ko) 2011-04-20 2016-01-29 주식회사 셀앤바이오 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
WO2012149607A1 (en) 2011-05-03 2012-11-08 Commonwealth Scientific And Industrial Research Organisation Method for detection of a neurological disease
GB201108490D0 (en) 2011-05-18 2011-07-06 Ucl Business Plc Methods and uses
WO2012159027A2 (en) 2011-05-19 2012-11-22 President And Fellows Of Harvard College Osw-1 analogs and conjugates, and uses thereof
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CN103648532A (zh) 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
WO2013008402A1 (ja) 2011-07-08 2013-01-17 シャープ株式会社 薄膜トランジスタ基板及びそれを備えた表示装置
GB201113482D0 (en) 2011-08-04 2011-09-21 Univ Liverpool Assay
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2758077B1 (en) 2011-09-19 2018-12-19 University Of The Witwatersrand, Johannesburg Compounds for use in the treatment of alzheimer's disease
ES2656442T3 (es) 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US20140235495A1 (en) 2011-09-23 2014-08-21 Siemens Healthcare Diagnostics Inc. Cell response assay for cancer and methods of producing and using same
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
CA2858601C (en) 2011-12-08 2020-11-17 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
US9549953B2 (en) 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
US8764695B2 (en) 2012-09-28 2014-07-01 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
WO2013090857A1 (en) 2011-12-15 2013-06-20 THE UNITED STSTES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Identification of two novel biomarkers for niemann-pick disease type c
US20130164217A1 (en) 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
WO2013099806A1 (ja) 2011-12-29 2013-07-04 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
WO2013106572A1 (en) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
CA2863964C (en) 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US9475840B2 (en) 2012-02-27 2016-10-25 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2013144957A1 (en) 2012-03-26 2013-10-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
WO2013169890A1 (en) 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
FR2994803B1 (fr) 2012-08-30 2016-02-26 Oreal Modulation de la forme des fibres keratiniques
EP2890788A1 (en) 2012-08-31 2015-07-08 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
DK2900061T3 (da) * 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
RU2689674C2 (ru) 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
EP2922861A4 (en) 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
US9066928B1 (en) 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
US9433665B2 (en) 2013-01-11 2016-09-06 Cyvax, Inc. Vaccines for protection from and treatment of alzheimer's disease
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
JP6379113B2 (ja) 2013-02-26 2018-08-22 バクスアルタ インコーポレイテッド 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US9879076B2 (en) 2013-03-15 2018-01-30 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
EP2978446B1 (en) 2013-03-27 2020-03-04 The General Hospital Corporation Anti-cd33 antibody for use in treating alzheimer's disease
LT2994160T (lt) 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
JP2016520615A (ja) 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
WO2014206899A1 (en) 2013-06-25 2014-12-31 Icm (Institut Du Cerveau Et De La Moelle Épinière) Boosting treg cells for treating alzheimer disease and related disorders
US9645155B2 (en) 2013-08-28 2017-05-09 University Of South Florida Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβ40 aggregates
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015038446A1 (en) 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use
WO2015051850A1 (en) 2013-10-11 2015-04-16 Universität Für Bodenkultur Wien Compositions containing galectin-3 modulators for the treatment of bone disorders
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
GB201319761D0 (en) 2013-11-08 2013-12-25 Nordic Bioscience As Biomarkers of disease progression
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
EP3086846B1 (en) 2013-12-27 2019-02-20 Dignity Health Diagnosing alzheimer's disease
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US10421958B2 (en) 2014-02-05 2019-09-24 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
SG11201606490YA (en) 2014-02-08 2016-09-29 Genentech Inc Methods of treating alzheimer's disease
JP2017512205A (ja) * 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法
ES2723774T3 (es) 2014-03-11 2019-09-02 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
WO2015159963A1 (ja) 2014-04-16 2015-10-22 協和発酵キリン株式会社 ヒトｃｓｆの毒性を測定する方法
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
AU2015258814B2 (en) 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
US20150377905A1 (en) 2014-06-25 2015-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of kawasaki disease
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016000156A1 (en) 2014-06-30 2016-01-07 Microsoft Technology Licensing, Llc Managing data with flexible schema
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
JP6464255B2 (ja) 2014-08-04 2019-02-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016024627A1 (ja) 2014-08-14 2016-02-18 国立大学法人広島大学 早産および／または低体重児出産のリスク判定方法およびそのためのキット
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US10328051B2 (en) 2014-09-22 2019-06-25 Zoser B. Salama Proline or proline derivatives for the treatment of dementia
MX2017004205A (es) 2014-10-01 2017-07-11 Dow Global Technologies Llc Estructura multicapa y articulos termoformados fabricados a partir de la misma.
US9921230B2 (en) 2014-10-08 2018-03-20 Rhode Island Hospital Methods for diagnosis and treatment of concussion or brain injury
WO2016059453A1 (en) 2014-10-16 2016-04-21 Fundacion Fraunhofer Chile Research Biomarkers and therapeutic targets for alzheimer's disease
AU2015343425A1 (en) 2014-11-04 2017-05-25 Dana-Farber Cancer Institute, Inc. Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
SI3221349T1 (sl) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2016120843A1 (en) 2015-01-29 2016-08-04 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
JP7297408B2 (ja) 2015-02-06 2023-06-26 セル アイディーエックス， インコーポレイテッド 抗原をカップリングさせた免疫試薬
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
GB201504432D0 (en) 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
US10828413B2 (en) 2015-03-27 2020-11-10 Eliaz Therapeutics, Inc. Patient selective apheresis
US12109346B2 (en) 2015-03-27 2024-10-08 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
GB201505239D0 (en) 2015-03-27 2015-05-13 Neuro Bio Ltd Antibody
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
WO2016183104A1 (en) 2015-05-11 2016-11-17 Genentech, Inc. Compositions and methods of treating lupus nephritis
GB201508276D0 (en) 2015-05-14 2015-06-24 Electrophoretics Ltd A casein kinase 1 delta inhibitor
US10174121B2 (en) 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
SG10202108116SA (en) 2015-06-08 2021-08-30 Debiopharm International S A Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
US10203342B2 (en) 2015-06-11 2019-02-12 Nanosomix, Inc. Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
IL256445B2 (en) 2015-06-30 2023-03-01 Nanotics Llc Compositions and methods related to absorbent particles
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
FI3334761T3 (fi) 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3353214B1 (en) 2015-09-25 2021-08-18 Universität Duisburg-Essen Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
HK1257801A1 (zh) 2015-10-28 2019-11-01 宾夕法尼亚州大学信托人 用於基因治疗的腺伴随病毒载体的鞘内给药
ES2921500T3 (es) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
US11459405B2 (en) 2015-12-28 2022-10-04 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
CN115925933A (zh) 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3436010B1 (en) 2016-03-29 2021-03-10 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CA3018253A1 (en) 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3464639A4 (en) 2016-05-31 2020-01-01 Goetzl, Edward, J. DIAGNOSTIC METHOD AND DRUG EFFECT TEST METHOD FOR DEMENTIA WITH THE USE OF ASTROCYTE-DERIVED EXOSOMES
WO2017218911A1 (en) 2016-06-17 2017-12-21 Abbott Laboratories BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
EP4295853A3 (en) 2016-06-28 2024-03-06 Emergent BioDefense Operations Lansing LLC Formulations of brincidofovir
PL3484916T3 (pl) 2016-07-12 2021-07-19 H. Lundbeck A/S Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania
US12123874B2 (en) 2016-07-18 2024-10-22 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
CA3030754C (en) 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
CN107652342A (zh) 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
EP3502248B1 (en) 2016-08-09 2024-05-29 National University Corporation Tokyo Medical and Dental University Antibodies against hmgb1, and composition comprising same for treating or preventing alzheimer's disease
US10076552B2 (en) 2016-08-09 2018-09-18 DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
US20190275040A1 (en) 2016-09-26 2019-09-12 Yale University Compounds and methods for treating or preventing alzheimer's disease
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018115003A2 (en) 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
AU2017384126B2 (en) 2016-12-20 2025-01-23 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
EP3573648B1 (en) 2017-01-25 2023-11-22 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
KR20240095466A (ko) 2017-01-30 2024-06-25 내션얼 리서치 카운슬 오브 캐나다 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US10473672B2 (en) 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
JP7165995B2 (ja) 2017-02-21 2022-11-07 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
US20190374650A1 (en) 2017-02-22 2019-12-12 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer/biomacromolecule conjugates
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
CN108728465A (zh) 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
AU2018264321B2 (en) 2017-05-08 2025-03-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
US20200061095A1 (en) 2017-05-12 2020-02-27 Galectin Sciences, Llc Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
MX2019012381A (es) 2017-05-18 2020-01-23 Hoffmann La Roche Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
US11214835B1 (en) 2017-06-06 2022-01-04 University Of South Florida Methods and compositions for diagnosis and management of neurodegerative diseases
SG11201912010XA (en) 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy
US20210017247A1 (en) 2017-07-03 2021-01-21 Torque Therapeutics, Inc. Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
MX2020000435A (es) 2017-07-14 2020-08-17 Cytomx Therapeutics Inc Anticuerpos anti-cd166 y usos de estos.
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US20190029970A1 (en) 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
EP3661502A4 (en) 2017-08-03 2020-12-02 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES
ES2933256T3 (es) 2017-08-08 2023-02-03 Hoffmann La Roche Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG
CN107881160A (zh) 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
MX2020004185A (es) 2017-09-27 2021-01-08 Univ Southern California Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
EP3466975A1 (en) 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
WO2019074840A1 (en) 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
BR112020007405A2 (pt) 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
JP7252953B2 (ja) 2017-10-25 2023-04-05 エアラン セル テクノロジーズ， インコーポレイテッド Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法
AU2018361991A1 (en) 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019094679A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of California BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs)
CU20200042A7 (es) 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
JP2021508246A (ja) 2017-12-21 2021-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
CN109985231A (zh) 2018-01-02 2019-07-09 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗痴呆症的药物中的应用
EP3737472A1 (en) 2018-01-09 2020-11-18 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
KR101868343B1 (ko) 2018-01-16 2018-06-18 재단법인대구경북과학기술원 콧물 시료의 베타 아밀로이드 올리고머를 이용한 알츠하이머 질환의 진행 단계 스크리닝용 조성물 및 이를 이용한 알츠하이머 질환의 진행 단계 스크리닝 방법
JP7539834B2 (ja) 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
WO2019161384A1 (en) 2018-02-19 2019-08-22 New York University Tau single domain antibodies
CN112040959A (zh) 2018-02-23 2020-12-04 真和制药有限公司 通过阻断vista和其结合伴侣的相互作用治疗癌症
US11819488B2 (en) 2018-02-23 2023-11-21 Rhnanopharma Nanosuspensions of salsalate and methods of using the same
CN112272677B (zh) 2018-02-26 2024-10-29 米纳瓦生物技术公司 使用抗muc1＊抗体的诊断方法
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019186276A2 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
EP3773500A4 (en) 2018-03-29 2022-03-16 Microvascular Therapeutics LLC COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
EP3773916A4 (en) 2018-04-04 2021-12-15 TrueBinding, Inc. PROCEDURES AND COMPOSITIONS FOR BLOCKING THE INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
WO2019198825A1 (ja) 2018-04-13 2019-10-17 国立大学法人京都大学 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬
JP7475283B2 (ja) 2018-04-16 2024-04-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト キレート化された放射性核種に対する抗体
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
KR102523019B1 (ko) 2018-05-30 2023-04-18 내셔날 헬스 리서치 인스티튜트 항-a베타 항체 및 이의 용도
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
PT3810128T (pt) 2018-06-19 2022-11-09 Univ Pablo De Olavide Composições para tratar e/ou prevenir doenças de agregação de proteinas
WO2019246422A1 (en) 2018-06-20 2019-12-26 Sanford Burnham Prebys Medical Discovery Institute Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of alzheimer's disease
US20220267460A1 (en) 2018-07-11 2022-08-25 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2021000778A (es) 2018-07-24 2021-03-31 Eisai R&D Man Co Ltd Metodos de tratamiento y prevencion de la enfermedad de alzheimer.
CN121248772A (zh) 2018-08-17 2026-01-02 Ab工作室有限公司 催化抗体和其使用方法
EP3845559A4 (en) 2018-08-31 2022-12-28 Bloom Technology Corporation ANTIBODIES FOR ADVANCED GLYCATION TERMINAL PRODUCTS AND THEIR USE
EP3849598A4 (en) 2018-09-11 2022-07-06 Washington University Anti-trem-2 agonist antibodies
MX2021003156A (es) 2018-09-18 2021-05-14 1 Globe Biomedical Co Ltd Tratamiento para la enfermedad del higado graso no alcoholico.
JP7475687B2 (ja) 2018-09-21 2024-04-30 国立大学法人 東京医科歯科大学 ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
KR102862077B1 (ko) 2018-10-04 2025-09-18 게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
WO2020069621A1 (en) 2018-10-04 2020-04-09 University Of Manitoba Novel biomarker for alzheimer's disease in human
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
KR20210078502A (ko) 2018-10-18 2021-06-28 펀더멘탈 파마 게엠베하 Nmda 수용체-매개 독성을 조절하는 신규 수단
EP3643319A1 (en) 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
CN113508135A (zh) 2018-10-29 2021-10-15 比奥根Ma公司 增强血脑屏障转运的人源化和稳定化的fc5变体
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
WO2020113164A1 (en) 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
WO2020117560A1 (en) 2018-12-04 2020-06-11 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
WO2020123492A1 (en) 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
JP2022037257A (ja) 2018-12-27 2022-03-09 クリニジェン株式会社 アルツハイマー病を治療又は予防する為の抗ウイルス剤及びその使用
CA3125302A1 (en) 2019-01-18 2020-07-23 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
CN111518205B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
WO2020163817A1 (en) 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
PL240124B1 (pl) 2019-02-21 2022-02-21 Univ Jagiellonski Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
US20220160710A1 (en) 2019-03-08 2022-05-26 University Of Virginia Patent Foundation Compositions and methods for treating or preventing alzheimer's disease
US11833214B2 (en) 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
US20220177560A1 (en) 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
SG11202110810WA (en) 2019-03-29 2021-10-28 Torque Therapeutics Inc Immunotherapeutic compositions and use thereof
EP3947395A1 (en) 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
CA3132202A1 (en) 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
KR20220012231A (ko) 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
EA202192891A1 (ru) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин
JP7561141B2 (ja) 2019-04-26 2024-10-03 イミュノジェン・インコーポレーテッド カンプトテシン誘導体
DE202020006093U1 (de) 2019-05-06 2025-04-09 The Regents Of The University Of California Nicht-HLA-Marker der Transplantatabstoßung
WO2020225799A2 (en) 2019-05-09 2020-11-12 University Of The Witwatersrand, Johannesburg A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
WO2020236679A1 (en) 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CN112111012B (zh) 2019-06-20 2023-07-04 成都恩沐生物科技有限公司 共价多特异性抗体
EP3986439A4 (en) 2019-06-21 2023-10-04 University of Kansas COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF BRAIN DISEASES
CN114401744B (zh) 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
US20230121775A1 (en) 2019-06-26 2023-04-20 Amunix Pharmaceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
US20220380454A1 (en) 2019-06-28 2022-12-01 The Regents Of The University Of California Methods and compositions for treating alzheimer's disease
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
US20220267776A1 (en) 2019-07-05 2022-08-25 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
JP7194085B2 (ja) 2019-07-09 2022-12-21 日立Astemo株式会社 操舵制御装置、操舵制御方法、及び操舵制御システム
EP3999169A4 (en) 2019-07-15 2023-09-06 Cochlear Limited TRANSCUTANEOUS DATA AND ENERGY COMMUNICATION LINK
WO2021011673A2 (en) 2019-07-16 2021-01-21 Ming Jin Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
DE102019119426A1 (de) 2019-07-17 2021-01-21 Endress+Hauser SE+Co. KG Feldgerät der Automatisierungstechnik
WO2021009868A1 (ja) 2019-07-17 2021-01-21 株式会社東芝 太陽電池モジュールおよびタンデム型太陽電池
WO2021012082A1 (zh) 2019-07-19 2021-01-28 莫丁丁 β—淀粉样蛋白环状核糖核酸、多肽及其应用
AU2020325315A1 (en) 2019-08-07 2022-03-24 Aqualung Therapeutics Corp. Anti-NAMPT antibodies and uses thereof
JP7813221B2 (ja) 2019-08-14 2026-02-12 ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト カスパーゼ－２バリアント
EP4021579A1 (en) 2019-08-30 2022-07-06 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
US20220332757A1 (en) 2019-09-09 2022-10-20 Wuhan Yzy Biopharma Co., Ltd. Split intein and preparation method for recombinant polypeptide using the same
CA3153700A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
EP4028040A2 (en) 2019-09-09 2022-07-20 Axon Neuroscience SE Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2021050645A1 (en) 2019-09-12 2021-03-18 Genentech, Inc. Compositions and methods of treating lupus nephritis
US11202068B2 (en) 2019-09-16 2021-12-14 Mediatek Inc. Method and apparatus of constrained cross-component adaptive loop filtering for video coding
CA3151223A1 (en) 2019-09-17 2021-03-25 Pravin T.P. Kaumaya Human anti-pd-l1 peptide vaccines and methods of their use
CN114616031A (zh) 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
US20240050562A1 (en) 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
EP4041308A1 (en) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN112641953A (zh) 2019-10-10 2021-04-13 复旦大学 一种靶向功能分子修饰的抗体复合物
MX2022004678A (es) 2019-10-22 2022-08-15 Biogen Ma Inc Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
WO2021087245A1 (en) 2019-10-30 2021-05-06 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
GB201915855D0 (en) 2019-10-31 2019-12-18 Univ Oxford Innovation Ltd An extracellular vesicle
CN115175920B (zh) 2019-11-13 2025-10-31 阿穆尼克斯制药公司 加条形码的xten多肽及其组合物以及其制备和使用方法
US20230203532A1 (en) 2019-11-28 2023-06-29 Mcmaster University Recombinant polypeptides for programming extracellular vesicles
EP4684799A2 (en) 2019-12-06 2026-01-28 TrueBinding, Inc. Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof
US20230046007A1 (en) 2019-12-17 2023-02-16 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
TWI766512B (zh) 2020-01-02 2022-06-01 瑞士商赫孚孟拉羅股份公司 用於判定腦中的治療性抗體量之方法
WO2021146218A1 (en) 2020-01-13 2021-07-22 Truebinding, Inc. Anti-gal3 antibodies and methods of use
KR20220131279A (ko) 2020-01-21 2022-09-27 상하이 헨리우스 바이오테크, 인크. 항lag3단일 클론 항체 및 그 제조 방법과 응용
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
WO2021157634A1 (ja) 2020-02-05 2021-08-12 大日本住友製薬株式会社 タウオパチーおよび認知症関連疾患の判定薬および判定方法
WO2021163346A2 (en) 2020-02-12 2021-08-19 The Scripps Research Institute Long-acting gm-csf and methods of use
WO2021163681A2 (en) 2020-02-14 2021-08-19 The Trustees Of Columbia University In The City Of New York Combination of retromer pharmacological chaperones and exogenous retromer for the treatment of alzheimer's disease and other neurodegenerative diseases and disorders
EP4107177A4 (en) 2020-02-17 2024-06-19 Board of Regents, The University of Texas System CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTHO) AND USES THEREOF
CA3174575A1 (en) 2020-03-02 2021-09-10 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
GB202003428D0 (en) 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens
CN113384710A (zh) 2020-03-14 2021-09-14 杭州星鳌生物科技有限公司 新型免疫激动剂复合物的组成及其在抗多种疾病药物中的应用
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US20230143984A1 (en) 2020-03-20 2023-05-11 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
WO2021195020A1 (en) 2020-03-23 2021-09-30 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
KR20220156934A (ko) 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
TW202342093A (zh) 2020-03-24 2023-11-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
US20230141177A1 (en) 2020-03-31 2023-05-11 The University Of British Columbia Antibodies to misfolded amyloid beta
WO2021207273A1 (en) 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics
CA3174646A1 (en) 2020-04-07 2021-10-14 Pieter Muntendam Methods and compositions for preventing and treating retinal nerve damage
CN115702003A (zh) 2020-04-23 2023-02-14 瑞美德生物医药科技有限公司 趋化因子受体4(cxcr4)拮抗剂抗体
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
US20230226016A1 (en) 2020-05-29 2023-07-20 The Regents Of University Of California Agents and methods for treating tauopathies
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
US20230235075A1 (en) 2020-06-02 2023-07-27 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4161520A1 (en) 2020-06-05 2023-04-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Acvr1 (alk2) receptor inhibition to treat neurological diseases
KR102225447B1 (ko) 2020-06-16 2021-03-08 부산대학교 산학협력단 구강 세균의 군집을 이용한 알츠하이머 진단용 바이오마커 및 이의 용도
CN115916827A (zh) 2020-06-19 2023-04-04 豪夫迈·罗氏有限公司 免疫活化Fc结构域结合分子
IL299215A (en) 2020-06-25 2023-02-01 Medimmune Ltd Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
US20210403644A1 (en) 2020-06-29 2021-12-30 University Of South Carolina Method For The Degradation Of Endogenous Protein
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
US20230285588A1 (en) 2020-07-20 2023-09-14 Neotx Therapeutics Ltd. Superantigen conjugate for use in methods and compositions for treating cancer
IL299815A (en) 2020-07-20 2023-03-01 Genentech Inc Methods for characterizing antibodies from the middle down
BR112022027096A2 (pt) 2020-07-21 2023-04-25 Amunix Pharmaceuticals Inc Composições e métodos relacionados a agentes terapêuticos ativáveis
TWI905235B (zh) 2020-07-29 2025-11-21 美商當康生物科技有限公司 抗cd93之構築體及其用途
JP2023536851A (ja) 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
PH12023550179A1 (en) 2020-07-30 2023-12-04 Unigen Inc A standardized bioflavonoid composition for regulation of homeostasis of host defense mechanism
AU2021322054A1 (en) 2020-08-03 2023-01-05 F. Hoffmann-La Roche Ag Improved antigen binding receptors
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
KR20230080397A (ko) 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신
AU2021321206A1 (en) 2020-08-07 2023-03-09 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
EP4198051A4 (en) 2020-08-11 2024-05-01 Kanaph Therapeutics Inc. FUSION PROTEIN WITH IL-12 AND ANTI-FAP ANTIBODIES AND USE THEREOF
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド Ｃｃｒ８抗体及びその用途
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
CN116724046A (zh) 2020-09-17 2023-09-08 欧萨尔普罗席纳有限公司 用于治疗阿尔茨海默病之β淀粉样蛋白疫苗
IL301262A (en) 2020-09-18 2023-05-01 Othair Prothena Ltd Multiepitope vaccine for the treatment of alzheimer's disease
US20230366884A1 (en) 2020-09-18 2023-11-16 Pieris Pharmaceuticals Gmbh Biomarker methods and uses
CN116322691A (zh) 2020-09-24 2023-06-23 豪夫迈·罗氏有限公司 T细胞双特异性抗体相关不良反应的预防或减轻
WO2022072538A1 (en) 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
IL301956A (en) 2020-10-07 2023-06-01 Dren Bio Inc Antibodies against dectin-1 and methods of using them
CN115052892B (zh) 2020-10-16 2023-07-07 礼新医药科技(上海)有限公司 抗ccr8单克隆抗体及其用途
JP2023547447A (ja) 2020-10-28 2023-11-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改良型抗原結合受容体
WO2022101120A1 (en) 2020-11-10 2022-05-19 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell engaging agent-related adverse effects
US20240026009A1 (en) 2020-12-08 2024-01-25 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
WO2022148732A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
EP4284824A4 (en) 2021-01-27 2025-03-12 AbelZeta Inc. CHIMERIC ANTIGEN RECEPTORS TARGETING CD20
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
AU2022224066A1 (en) 2021-02-19 2023-09-07 Angeles Therapeutics, Inc. Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
EP4308157A1 (en) 2021-03-15 2024-01-24 Genentech, Inc. Compositions and methods of treating lupus nephritis
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
MX2023010819A (es) 2021-03-18 2023-09-28 Seagen Inc Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
CN117355319A (zh) 2021-03-23 2024-01-05 皮里斯制药有限责任公司 用于癌症治疗的her2/4-1bb双特异性融合蛋白
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
US20240165153A1 (en) 2021-03-24 2024-05-23 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
JP2024512645A (ja) 2021-04-02 2024-03-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 二重特異性分子並びに関連する組成物及び方法
AU2022262600A1 (en) 2021-04-20 2023-10-05 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
WO2022223651A1 (en) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Prevention or mitigation of nk cell engaging agent-related adverse effects
JP2024515968A (ja) 2021-04-26 2024-04-11 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体製剤およびその使用法
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
MX2023012699A (es) 2021-04-30 2023-11-21 Hoffmann La Roche Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
WO2022235622A2 (en) 2021-05-04 2022-11-10 Biocove Llc Cd20 targeting fusion proteins and methods of use thereof
KR20240007184A (ko) 2021-05-12 2024-01-16 제넨테크, 인크. 미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
CA3218343A1 (en) 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN118139641A (zh) 2021-06-04 2024-06-04 Xencor股份有限公司 结合cd20和cd3的双重特异性抗体的剂量施用
WO2022261113A2 (en) 2021-06-08 2022-12-15 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
US20250002601A1 (en) 2021-06-09 2025-01-02 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
JP2024523838A (ja) 2021-06-09 2024-07-02 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質
AU2022293581A1 (en) 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
AU2022294106A1 (en) 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
CN117157098A (zh) 2021-06-22 2023-12-01 荣昌生物制药(烟台)股份有限公司 一种药物组合及其用途
TW202325732A (zh) 2021-06-25 2023-07-01 大陸商南京艾美斐生物醫藥科技有限公司 抗-ccr8抗体及其用途
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
EP4371125A1 (en) 2021-07-13 2024-05-22 Genentech, Inc. Multi-variate model for predicting cytokine release syndrome
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
JP2024528631A (ja) 2021-07-22 2024-07-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロ二量体Ｆｃドメイン抗体
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20240353426A1 (en) 2021-08-13 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for Diagnosing and Treating Ischemic Eye Disease
TW202330595A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118591388A (zh) 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2023051727A1 (zh) 2021-09-30 2023-04-06 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途
AR127271A1 (es) 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
CN115746134A (zh) 2021-10-15 2023-03-07 深圳市睿盟创新生物科技有限公司 半乳糖凝集素-3的免疫测定
KR20230060546A (ko) 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
WO2023077099A1 (en) 2021-10-29 2023-05-04 Zielbio, Inc. Cancer specific plectin-1 specific antibodies and methods of use thereof
CA3238590A1 (en) 2021-11-09 2023-05-19 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
JP2024543152A (ja) 2021-11-25 2024-11-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改善された抗原結合受容体
CN118524854A (zh) 2021-12-17 2024-08-20 北京加科思新药研发有限公司 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途
CN119930823A (zh) 2021-12-23 2025-05-06 乐普创一生物科技（上海）有限公司 抗ccr8抗体及其应用
WO2023125611A1 (zh) 2021-12-29 2023-07-06 四川汇宇制药股份有限公司 靶向cd3的抗体及多特异性抗体及其用途
EP4463485A4 (en) 2022-01-12 2026-02-25 Biomolecular Holdings Llc Tetrahedral antibodies
TW202337912A (zh) 2022-01-12 2023-10-01 美商生質分子控股有限責任公司 四面體抗體
EP4467571A4 (en) 2022-01-20 2026-02-25 Shanghai Junshi Biosciences Co Ltd Bispecific Antibody: Anti-CD3 and Anti-CD20 and its Use
EP4466020A4 (en) 2022-01-21 2026-04-15 Lyvgen Biopharma Holdings Ltd Multi-specific antibodies and their uses in avidity receptor cross-linking and immune modulation
KR20230119859A (ko) 2022-02-08 2023-08-16 연세대학교 산학협력단 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
TW202400643A (zh) 2022-02-28 2024-01-01 日商帝人製藥股份有限公司 神經退化性疾病之治療劑
GB202203070D0 (en) 2022-03-04 2022-04-20 Iksuda Therapeutics Ltd Anti-canag antibody conjugate
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
CN116789820A (zh) 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
CA3260121A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier ANTI-GAL3 ANTIBODIES AND COMPOSITIONS
US20250333487A1 (en) 2022-03-25 2025-10-30 Cytomx Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
IL315845A (en) 2022-04-04 2024-11-01 Dren Bio Inc Anti-dectin-1 antibodies and methods of using them
US20250223364A1 (en) 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
JP2025512953A (ja) 2022-04-11 2025-04-22 アストラゼネカ・アクチエボラーグ Ｔ細胞結合タンパク質
TWI882313B (zh) 2022-04-13 2025-05-01 美商建南德克公司 治療性蛋白質之醫藥組成物及使用方法
CN119013300A (zh) 2022-04-13 2024-11-22 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
US20250325687A1 (en) 2022-04-15 2025-10-23 Mabsoft Therapeutics (Shanghai) Co., Ltd. Conjugate comprising toll-like receptor agonist
CN117003872A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
IL316747A (en) 2022-05-03 2025-01-01 Xencor Inc Lymphoma treatment methods
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
CA3245954A1 (en) 2022-05-25 2023-11-30 Innate Pharma NECTIN-4 LIAISON OFFICERS
US20230416412A1 (en) 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
CN117323429A (zh) 2022-07-01 2024-01-02 广东克冠达医药科技有限公司 Cd101的抗体及其用途
JP2025524628A (ja) 2022-07-12 2025-07-30 シートムエックス セラピューティクス，インコーポレイテッド Ｅｐｃａｍイムノコンジュゲート及びその使用
WO2024026407A1 (en) 2022-07-28 2024-02-01 The Board Of Regents Of The University Of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
WO2024036148A1 (en) 2022-08-08 2024-02-15 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117051537A (zh) 2023-07-03 2023-11-14 五邑大学 一种乙酰化葡甘聚糖静电纺丝膜及其制备方法与应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Anti-TIM3 Antibody Promotes T Cell IFN-g–Mediated Antitumor Immunity and Suppresses Established Tumors;Shin Foong Ngiow et al.;Microenvironment and Immunology;第71卷(第10期);全文 *
Mechanical Entrapment Is Insufficient and Intercellular Adhesion Is Essential for Metastatic Cell Arrest in Distant Organs;Olga V. Glinskii et al.;Neoplasia;第7卷(第5期);第522页摘要第18-22行、第523页左栏材料方法部分第1-4行 *
Olga V. Glinskii et al..Mechanical Entrapment Is Insufficient and Intercellular Adhesion Is Essential for Metastatic Cell Arrest in Distant Organs.Neoplasia.2005,第7卷(第5期),第522页摘要第18-22行、第523页左栏材料方法部分第1-4行. *
半乳糖凝集素 及其相关抑制剂的研究进展;徐跃 等;中国生化药物杂志;第32卷(第5期);第420页第3.4节 *
徐跃 等.半乳糖凝集素 及其相关抑制剂的研究进展.中国生化药物杂志.2011,第32卷(第5期),第420页第3.4节. *

Also Published As

Publication number Publication date
EP3658172A4 (en) 2021-05-05
JP2023145569A (ja) 2023-10-11
JP7368856B2 (ja) 2023-10-25
US12227567B2 (en) 2025-02-18
US20200223921A1 (en) 2020-07-16
WO2019023247A1 (en) 2019-01-31
JP7789386B2 (ja) 2025-12-22
US20250171539A1 (en) 2025-05-29
AU2018308088A1 (en) 2020-02-20
AU2018308088B2 (en) 2025-05-29
CA3070446A1 (en) 2019-01-31
EP3658172A1 (en) 2020-06-03
CN111201030A (zh) 2020-05-26
US20240182564A1 (en) 2024-06-06
JP2020529469A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
CN111201030B (zh) 通过阻断tim-3和其配体的相互作用治疗癌症
JP7431211B2 (ja) 抗メソテリン抗体
JP2026053616A (ja) 癌の治療のためのクローディン１８．２に対する抗体を含む治療法
JP6586087B2 (ja) Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
EP2848631B1 (en) Use of an anti-ang2 antibody
US20250333506A1 (en) Antibodies specific to delta 1 chain of t cell receptor
US20210363255A1 (en) Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides
CA3213216A1 (en) Tgf-beta inhibitors and use thereof
JP2021500320A (ja) 癌の治療のための配合剤
US20260077043A1 (en) Combination therapy
HK40116807A (en) Antibodies specific to delta 1 chain of t cell receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Zhenhe Pharmaceutical Co.,Ltd.

Address before: California, USA

Applicant before: Immunity Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment